1. Home
  2. ICCM vs CTSO Comparison

ICCM vs CTSO Comparison

Compare ICCM & CTSO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo IceCure Medical Ltd.

ICCM

IceCure Medical Ltd.

HOLD

Current Price

$0.69

Market Cap

45.5M

Sector

N/A

ML Signal

HOLD

Logo Cytosorbents Corporation

CTSO

Cytosorbents Corporation

HOLD

Current Price

$0.71

Market Cap

49.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ICCM
CTSO
Founded
2006
1997
Country
Israel
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
45.5M
49.7M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
ICCM
CTSO
Price
$0.69
$0.71
Analyst Decision
Strong Buy
Buy
Analyst Count
1
2
Target Price
$2.50
$5.38
AVG Volume (30 Days)
374.5K
123.7K
Earning Date
11-19-2025
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$2,975,000.00
$36,979,520.00
Revenue This Year
$2.92
$11.93
Revenue Next Year
$57.81
$21.22
P/E Ratio
N/A
N/A
Revenue Growth
N/A
23.89
52 Week Low
$0.59
$0.60
52 Week High
$1.66
$1.61

Technical Indicators

Market Signals
Indicator
ICCM
CTSO
Relative Strength Index (RSI) 41.53 46.80
Support Level $0.67 $0.70
Resistance Level $0.72 $0.85
Average True Range (ATR) 0.05 0.07
MACD 0.01 0.01
Stochastic Oscillator 61.31 52.60

Price Performance

Historical Comparison
ICCM
CTSO

About ICCM IceCure Medical Ltd.

Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.

About CTSO Cytosorbents Corporation

CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales and Distributors/strategic partners in United States, Germany and Other Countries. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.

Share on Social Networks: